Rynki

Twoje finanse

Biznes

Forum

SOPHARMA AD: Sales revenues for October 2023

Spis treści:

1. REPORT

reklama

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY


Spis załączników:
Sales Revenues October 2023 espi.pdf  (REPORT)

przewiń, aby zobaczyć całą tabelę
POLISH FINANCIAL SUPERVISION AUTHORITY
UNI - EN REPORT No 197 / 2023
Date of issue: 2023-11-20
Short name of the issuer
SOPHARMA AD
Subject
Sales revenues for October 2023
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Sofia, Bulgaria, November 20, 2023 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that for the month of October 2023, the Company realized an increase in sales of 45% compared to the same month of the previous year, incl. 53% increase in domestic sales and 42% increase in export sales.
For the ten months from the beginning of 2023, sales increased by a total of 18%, incl. a 5% increase in domestic sales and a 27% increase in export sales.
Annexes
File Description
Sales Revenues October 2023 espi.pdfSales_Revenues_October_2023_espi.pdf Sales revenues for October 2023

przewiń, aby zobaczyć całą tabelę
SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

przewiń, aby zobaczyć całą tabelę
SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2023-11-20 Ognian Donev Executive Director
Źródło: Komunikaty spółek (ESPI)
powiązane
polecane
najnowsze
popularne
najnowsze
bankier na skróty